{"id":"W4387782335","doi":"10.1038/s41591-023-02593-0","title":"The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":true,"ca_institutions":"Zymeworks (Canada)","funders":"MacroGenics; NRG Oncology","keywords":"Medicine; Internal medicine; Refractory (planetary science); Adverse effect; Clinical endpoint; Cancer; Clinical trial; Oncology; Cohort; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001355228,0.001120331,0.001031026,0.0002436253,0.0003134679,0.0006173863,0.0005332591,0.0009650785,0.002387935],"category_scores_gemma":[0.0005243906,0.0002773442,0.0007027153,0.0002188167,0.00043338,0.0004616644,0.0002732917,0.002042852,0.000453111],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006044328,"about_ca_system_score_gemma":0.0009621948,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004822662,"about_ca_topic_score_gemma":0.001203712,"domain_scores_codex":[0.9997521,0.0001085082,0.00001024473,0.00004028913,0.00003096056,0.00005791674],"domain_scores_gemma":[0.9996729,0.00005584515,0.00007147705,0.00002054252,0.00002291279,0.0001563489],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6537508,0.06975764,0.005980719,0.001454364,0.001084301,0.0005464756,0.0003541707,0.003764582,0.1411081,0.0007834418,0.006849858,0.1145656],"study_design_scores_gemma":[0.5233797,0.4444137,0.01112105,0.00006071078,0.0005383894,0.0005411475,0.00005387661,0.002281852,0.01253762,0.0003659929,0.004678615,0.00002731954],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939123,0.001730367,0.0005325219,0.0003218881,0.00006209217,0.00160057,0.0007375587,0.00005586178,0.001046909],"genre_scores_gemma":[0.9884737,0.002289376,0.001575193,0.0007520064,0.0001227817,0.002495271,0.001847499,0.00002179066,0.002422479],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002387935,"threshold_uncertainty_score":0.007988453,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0182040159186513,"score_gpt":0.3508122363939516,"score_spread":0.3326082204753003,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}